Cotempla XR-ODT (Methylphenidate) Patent Expiration, LOE Window & CMS Spending

Cotempla XR-ODT (Methylphenidate) by Neos Therapeutics: FDA Orange Book LOE 2038-01-25, 1 AB generics, $10.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNeos Therapeutics
FDA Application & PathwayN205489 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-01-25
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$10.1M
2024 Medicare Part D Spend$192K
2024 Medicaid Spend$9.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel